Matching targeted therapies to tumor-specific gene mutations across tumor types improved survival in patients with advanced cancer, compared to those receiving non-matched, standard-of-care treatment, MD Anderson trial data revealed.
Long-term data from the center’s IMPACT trial, which compares treatments based on molecular profiling to standard-of-care treatments, showed the three-year, overall survival rate was 15 percent in...
In recent years, five new immunotherapy drugs have been approved to treat patients diagnosed with urinary cancer. But the drugs, which held...
In a small Phase II study of early-stage breast cancer patients with BRCA 1 and 2 mutations, researchers found that more than half of women...
In a randomized, Phase II trial led by researchers at MD Anderson, adding the PARP inhibitor veliparib to a standard chemotherapy agent improved overall response rates (ORR) in patients with small cell lung cancer (SCLC). Researchers also identified a select group of patients — those whose tumors expressed SLFN11 — who also saw a progression-free survival (PFS) and overall survival (OS) benefit, suggesting a promising biomarker for the...
For patients with advanced, inoperable stage 3 lung cancer, chemotherapy and a specialized form of radiation treatment known as proton...
High response rates to a pair of combination therapies point to potentially new options for a group of metastatic melanoma patients who have...
An advanced form of image-guided radiation therapy known as intensity modulated proton therapy (IMPT) has shown early promise for the treatment...
A new study from MD Anderson finds that women with early-stage breast cancer who had an intermediate risk recurrence score (RS)...
For women with a rare subtype of epithelial ovarian or peritoneum cancer, known as low-grade serous carcinoma (LGSC), hormone maintenance...
Breast cancer patients with dense breast tissue have almost a two-fold increased risk of developing disease in the other breast, according...